

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		A1	(11) International Publication Number:	WO 97/18833
A61K 38/22			(43) International Publication Date:	29 May 1997 (29.05.97)
(21) International Application Number:	PCT/US96/17718		(81) Designated States:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date:	4 November 1996 (04.11.96)		(Published)	<i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(30) Priority Data:	08/561,732	22 November 1995 (22.11.95)	US	
(71) Applicant:	AMGEN INC. [US/US]; Amgen Center, 1840 De Havilland Drive, Thousand Oaks, CA 91320-1789 (US).			
(72) Inventors:	PELLEYMOUNTER, Mary, Ann; 1909 Hillcrest Drive, Thousand Oaks, CA 91320 (US). TOOMBS, Christopher, Francis; 5076 Ladera Vista Drive, Camarillo, CA 93012 (US).			
(74) Agents:	ODRE, Steven, M. et al.; Amgen Inc., Amgen Center, 1840 De Havilland Drive, Thousand Oaks, CA 91320-1789 (US).			
(54) Title: METHODS OF INCREASING LEAN TISSUE MASS USING OB PROTEIN COMPOSITIONS				
(57) Abstract				
Methods of using OB protein compositions for increasing lean tissue mass are provided. Also provided are methods of using OB protein compositions for increasing insulin sensitivity, as well as increasing overall body strength and decreasing bone resorption.				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	IU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

METHODS OF INCREASING LEAN TISSUE MASS USING OB PROTEIN COMPOSITIONS

5

FIELD OF THE INVENTION

The present invention relates to methods of using OB protein compositions for increasing lean tissue
10 mass.

BACKGROUND

Although the molecular basis for obesity is largely unknown, the identification of the "OB gene" and protein encoded ("OB protein") has shed some light on mechanisms the body uses to regulate body fat deposition. Zhang et al., Nature 372: 425-432 (1994); see also, the Correction at Nature 374: 479 (1995). The OB protein is active in vivo in both ob/ob mutant mice (mice obese due to a defect in the production of the OB gene product) as well as in normal, wild type mice. The biological activity manifests itself in, among other things, weight loss. See generally, Barinaga, "Obese" Protein Slims Mice, Science 269: 475-476 (1995).

The other biological effects of OB protein are not well characterized. It is known, for instance, that in ob/ob mutant mice, administration of OB protein

results in a decrease in serum insulin levels, and serum glucose levels. It is also known that administration of OB protein results in a decrease in body fat. This was observed in both ob/ob mutant mice, as well as non-obese 5 normal mice. Pelleymounter et al., *Science* 269: 540-543 (1995); Halaas et al., *Science* 269: 543-546 (1995). See 10 also, Campfield et al., *Science* 269: 546-549 (1995) (Peripheral and central administration of microgram doses of OB protein reduced food intake and body weight of ob/ob and diet-induced obese mice but not in db/db obese mice.) In none of these reports have toxicities been observed, even at the highest doses.

15 The elucidation of other biological effects of the OB protein, particularly on animals which may not benefit from or may not need weight reduction, will provide additional uses for the OB protein.

20 One such use, as provided by the present invention, is in the increase in lean tissue mass.

25 Of course, modulation of diet and exercise is one way to increase muscle size. There are also compositions used to increase lean mass. Current compositions thought to increase lean tissue mass include anabolic steroids, such as testosterone and derivatives, and human growth hormone. These are noted to have undesirable side effects however. (The summary below is fully explained in Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, PA 18042) Chapter 50, at pages 948-1001.))

30 Human growth hormone, such as Protropin and Somatropin are noted to frequently cause hypercalciuria, 35 which usually regresses in 2 to 3 months. Hyperglycemia and frank diabetes mellitus are also noted to occur.

Myalgia and early morning headaches are noted to be relatively frequent, and occasionally cases of hypothyroidism and supersaturation of cholesterol in bile may occur. If the epiphyses are closed, the 5 hormone should not be used because continued stimulation of growth of the phalanges and jawbone, but not other bones, can cause abnormal body proportions.

Anabolic steroids increase athletic performance and aggressiveness. Their use has been condemned by the American College of Sports Medicine. Female performance is improved, but at the expense of virilization and acne vulgaris. Androgens cause hirsutism, deepening or hoarseness of the voice, 15 precocious puberty and epiphyseal closure in immature males, increased libido (in both male and female) priapism, oligospermia, and testicular atrophy, enlargement of the clitoris in the female, flushing, decreased ejaculatory volume and sperm population, 20 gynecomastia, hypersensitivity, acne, weight gain, edema and hypercalcemia. Prolonged use increases aggressiveness, sometimes enormously, and many assaults are stated to be attributable to androgen abuse. Paranoia-like and other psychotic behavior has been 25 reported. Biliary stasis and jaundice occur. There have been a few cases reported of hepatoma following long term therapy.

It is therefore desirable to have a 30 therapeutic or cosmetic composition which increases lean tissue mass without side effects seen in the presently available drugs.

SUMMARY OF THE INVENTION

The present invention stems from the observation that administration of OB protein to non-obese as well as obese animals results in an increase of lean tissue mass. Thus, OB protein has the capacity to act, in addition to acting as a weight reducing agent, as an agent affecting lean tissue mass. As such, numerous lean tissue-mass increasing therapies are contemplated, even for patients who would not necessarily benefit from weight reduction. Thus, one aspect of the present invention is the use of OB protein (or analogs or derivatives thereof) for increasing lean tissue mass.

15

In another aspect, the present invention relates to methods of treating diabetes, and reducing the levels of insulin necessary for the treatment of diabetes. The increase in lean tissue mass, with concomitant decrease in fat tissue mass, increases sensitivity to insulin. Therefore, the present methods relate to use of OB protein (or analogs or derivatives thereof) for decreasing the amount of insulin necessary for the treatment of diabetes.

25

DETAILED DESCRIPTION

As stated above, the methods of the present invention are those for increasing lean tissue mass in an individual. This increase in lean tissue mass has been observed to accompany a decrease in fat mass. Thus, even if administration of OB protein (or analogs or derivatives thereof) does not result in a desired amount of weight loss, administration of OB protein may be useful to reconfigure body mass in reducing body fat, while increasing lean mass.

Additionally, the increase in lean tissue mass may make an individual more sensitive to insulin, and thus the present methods of using OB protein (or analogs or derivatives thereof) are also related to increasing insulin sensitivity in a diabetic patient. While the precise mode of action is uncertain, lean tissue (e.g., muscle), as compared to fat tissue, may be more sensitive to the effects of insulin. Therefore, an increase in lean tissue may make available more cells which are sensitive to insulin. Further, elimination of fat (e.g., adipose) tissue may have the additional benefit of providing lean tissue with additional exposure to the peripheral circulation, where circulating insulin is found. It is therefore another aspect of the present invention that a method of increasing sensitivity to insulin is provided. Put another way, a method of decreasing the dosage of insulin needed by a diabetic is thus also provided.

20

The increase in lean tissue may be an increase in muscle tissue. Such increase is observed to be an overall increase, rather than localized to particular areas (e.g., Examples 1 and 2 below). As such, overall strength may increase. With the increase in overall strength, other benefits may result, such as a decrease in bone resorption, with the potential to reverse or improve frailty such as osteoporosis. In patients desiring improved athletic performance, an increase in overall strength may also provide as such. There may be an increase in red blood cell production or effectiveness, and an increase in oxygenated blood. As such, mental as well as physical performance may be improved.

35

The OB protein may be selected from recombinant murine set forth below (SEQ. ID No. 2), or recombinant human protein as set forth in Zhang et al., *Nature, supra*, herein incorporated by reference) or 5 those lacking a glutaminyl residue at position 28. (See Zhang et al., *Nature, supra*, at page 428.) One may also use the recombinant human OB protein analog as set forth in SEQ.ID.NO. 4, which contains 1) an arginine in place of lysine at position 35 and 2) a leucine in place of 10 isoleucine at position 74. (A shorthand abbreviation for this analog is the recombinant human R->K³⁵, L->I⁷⁴). The amino acid sequences for the recombinant human analog and recombinant murine proteins are set forth below with a methionyl residue at the -1 position, 15 however, as with any of the present OB proteins and analogs, the methionyl residue may be absent.

The murine protein is substantially homologous to the human protein, particularly as a mature protein, 20 and, further, particularly at the N-terminus. One may prepare an analog of the recombinant human protein by altering (such as substituting amino acid residues), in the recombinant human sequence, the amino acids which diverge from the murine sequence. Because the recombinant human protein has biological activity in 25 mice, such analog would likely be active in humans. For example, using a human protein having a lysine at residue 35 and an isoleucine at residue 74 according to the numbering of SEQ. ID NO. 4, wherein the first amino acid is valine, and the amino acid at position 146 is cysteine, one may substitute with another amino acid one 30 or more of the amino acids at positions 32, 35, 50, 64, 68, 71, 74, 77, 89, 97, 100, 105, 106, 107, 108, 111, 118, 136, 138, 142, and 145. One may select the amino 35 acid at the corresponding position of the murine protein, (SEQ. ID. NO. 2), or another amino acid.

One may further prepare "consensus" molecules based on the rat OB protein sequence. Murakami et al., Biochem.Biophys.Res. Comm. 209: 944-952 (1995) herein incorporated by reference. Rat OB protein differs from 5 human OB protein at the following positions (using the numbering of SEQ. ID. NO. 4): 4, **32**, 33, **35**, **50**, 68, **71**, **74**, **77**, 78, **89**, **97**, **100**, 101, 102, **105**, **106**, **107**, **108**, **111**, **118**, **136**, **138** and **145**. One may substitute with another amino acid one or more of the amino acids at 10 these divergent positions. The positions in bold print are those which in which the murine OB protein as well as the rat OB protein are divergent from the human OB protein, and thus, are particularly suitable for alteration. At one or more of these positions, one may 15 substitute an amino acid from the corresponding rat OB protein, or another amino acid.

The positions from both rat and murine OB protein which diverge from the mature human OB protein 20 are: 4, 32, 33, 35, 50, 64, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 118, 136, 138, 142, and 145. A human OB protein according to SEQ. ID. NO. 4 25 (with lysine at position 35 and isoleucine at position 74) having one or more of the above amino acids deleted or replaced with another amino acid, such as the amino acid found in the corresponding rat or murine sequence, may also be effective.

In addition, the amino acids found in rhesus 30 monkey OB protein which diverge from the mature human OB protein are (with identitites noted in parentheses in one letter amino acid abbreviation): 8 (S), 35 (R), 48(V), 53(Q), 60(I), 66(I), 67(N), 68(L), 89(L), 100(L), 108(E), 112(D), and 118(L). Since (as 35 described in Example 2, below) the recombinant human OB protein is active in cynomolgus monkeys, a human OB

protein according to SEQ. ID. NO. 4 (with lysine at position 35 and isoleucine at position 74) having one or more of the rhesus monkey divergent amino acids replaced with another amino acid, such as the amino acids in parentheses, may be effective. It should be noted that certain rhesus divergent amino acids are also those found in the above murine species (positions 35, 68, 89, 100 and 112). Thus, one may prepare a murine/rhesus/human consensus molecule having (using the numbering of SEQ.ID. NO. 4 having a lysine at position 35 and an isoleucine at position 74) having one or more of the amino acids at positions replaced by another amino acid: 4, 8, 32, 33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, and 145.

Other analogs may be prepared by deleting a part of the protein amino acid sequence. For example, the mature protein lacks a leader sequence (-22 to -1). One may prepare the following truncated forms of human OB protein molecules (using the numbering of SEQ. ID. NO. 4):

- (a) amino acids 98-146
- (b) amino acids 1-32
- 25 - (c) amino acids 40-116
- (d) amino acids 1-99 and (connected to)
112-146
- (e) amino acids 1-99 and (connected to)
112-146 having one or more of amino acids 100-111 placed
30 between amino acids 99 and 112.

In addition, the truncated forms may also have altered one or more of the amino acids which are divergent (in the rhesus, rat or murine OB protein) from 35 human OB protein. Furthermore, any alterations may be

in the form of altered amino acids, such as peptidomimetics or D-amino acids.

The present protein (herein the term "protein" 5 is used to include "peptide" and OB analogs, such as those recited infra, unless otherwise indicated) may also be derivatized by the attachment of one or more chemical moieties to the protein moiety. The chemically modified derivatives may be further formulated for 10 intraarterial, intraperitoneal, intramuscular, subcutaneous, intravenous, oral, nasal, pulmonary, topical or other routes of administration. Chemical modification of biologically active proteins has been found to provide additional advantages under certain 15 circumstances, such as increasing the stability and circulation time of the therapeutic protein and decreasing immunogenicity. See U.S. Patent No. 4,179,337, Davis et al., issued December 18, 1979. For a review, see Abuchowski et al., in Enzymes as 20 Drugs. (J.S. Holcerberg and J. Roberts, eds. pp. 367-383 (1981)). A review article describing protein modification and fusion proteins is Francis, Focus on Growth Factors 3: 4-10 (May 1992) (published by Mediscript, Mountview Court, Friern Barnet Lane, London 25 N20, OLD, UK).

The chemical moieties suitable for derivatization may be selected from among various water soluble polymers. The polymer selected should be water 30 soluble so that the protein to which it is attached does not precipitate in an aqueous environment, such as a physiological environment. Preferably, for therapeutic use of the end-product preparation, the polymer will be pharmaceutically acceptable. One skilled in the art 35 will be able to select the desired polymer based on such considerations as whether the polymer/protein conjugate

will be used therapeutically, and if so, the desired dosage, circulation time, resistance to proteolysis, and other considerations. For the present proteins and peptides, the effectiveness of the derivatization may be 5 ascertained by administering the derivative, in the desired form (i.e., by osmotic pump, or, more preferably, by injection or infusion, or, further formulated for oral, pulmonary or nasal delivery, for example), and observing biological effects as described 10 herein.

The water soluble polymer may be selected from the group consisting of, for example, polyethylene glycol, copolymers of ethylene glycol/propylene glycol, 15 carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random or non-random copolymers), and dextran or poly(n-vinyl 20 pyrrolidone)polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols, polystyrenemaleate and polyvinyl alcohol. Polyethylene glycol propionaldehyde may have advantages in 25 manufacturing due to its stability in water.

Fusion proteins may be prepared by attaching polyaminoacids to the OB protein (or analog) moiety. For example, the polyamino acid may be a carrier protein 30 which serves to increase the circulation half life of the protein. For the present therapeutic or cosmetic purposes, such polyamino acid should be those which have do not create neutralizing antigenic response, or other adverse response. Such polyamino acid may be selected 35 from the group consisting of serum album (such as human serum albumin), an antibody or portion thereof (such as

an antibody constant region, sometimes called "Fc") or other polyamino acids. As indicated below, the location of attachment of the polyamino acid may be at the N-terminus of the OB protein moiety, or other place, and 5 also may be connected by a chemical "linker" moiety to the OB protein.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene 10 glycol, the preferred molecular weight is between about 2 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and 15 manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the 20 polyethylene glycol to a therapeutic protein or analog).

The number of polymer molecules so attached may vary, and one skilled in the art will be able to ascertain the effect on function. One may 25 mono-derivatize, or may provide for a di-, tri-, tetra- or some combination of derivatization, with the same or different chemical moieties (e.g., polymers, such as different weights of polyethylene glycals). The proportion of polymer molecules to protein (or peptide) 30 molecules will vary, as will their concentrations in the reaction mixture. In general, the optimum ratio (in terms of efficiency of reaction in that there is no excess unreacted protein or polymer) will be determined by factors such as the desired degree of derivatization 35 (e.g., mono, di-, tri-, etc.), the molecular weight of

the polymer selected, whether the polymer is branched or unbranched, and the reaction conditions.

The chemical moieties should be attached to
5 the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art. E.g., EP 0 401 384 herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., Exp.
10 Hematol. 20: 1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those
15 to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residue. Those having a free carboxyl group may include aspartic acid residues, glutamic acid residues, and the C-terminal amino acid residue.
20 Sulphydrl groups may also be used as a reactive group for attaching the polyethylene glycol molecule(s). Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or
25 lysine group. Attachment at residues important for receptor binding should be avoided if receptor binding is desired.

One may specifically desire N-terminally
30 chemically modified protein. Using polyethylene glycol as an illustration of the present compositions, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein molecules in
35 the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected

N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally 5 pegylated material from a population of pegylated protein molecules. Selective N-terminal chemical modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the 10 N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved. For example, one may selectively N- 15 terminally pegylate the protein by performing the reaction at a pH which allows one to take advantage of the pKa differences between the ε-amino group of the lysine residues and that of the α-amino group of the N-terminal residue of the protein. By such selective 20 derivatization, attachment of a water soluble polymer to a protein is controlled: the conjugation with the polymer takes place predominantly at the N-terminus of the protein and no significant modification of other reactive groups, such as the lysine side chain amino 25 groups, occurs. Using reductive alkylation, the water soluble polymer may be of the type described above, and should have a single reactive aldehyde for coupling to the protein. Polyethylene glycol propionaldehyde, containing a single reactive aldehyde, may be used.

30 An N-terminally monopegylated derivative is preferred for ease in production of a therapeutic. N-terminal pegylation ensures a homogenous product as characterization of the product is simplified relative 35 to di-, tri- or other multi pegylated products. The use of the above reductive alkylation process for

preparation of an N-terminal product is preferred for ease in commercial manufacturing.

In yet another aspect of the present invention, provided are methods of using pharmaceutical compositions of the proteins, and derivatives. Such pharmaceutical compositions may be for administration by injection, or for oral, pulmonary, nasal, transdermal or other forms of administration. In general, comprehended by the invention are pharmaceutical compositions comprising effective amounts of protein or derivative products of the invention together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions include diluents of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength; additives such as detergents and solubilizing agents (e.g., Tween 80, Polysorbate 80), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol); incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. Hylauronic acid may also be used, and this may have the effect of promoting sustained duration in the circulation. Such compositions may influence the physical state, stability, rate of *in vivo* release, and rate of *in vivo* clearance of the present proteins and derivatives. See, e.g., Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, PA 18042) pages 1435-1712 which are herein incorporated by reference. The compositions may be prepared in liquid form, or may be in dried powder, such as lyophilized form. Implantable sustained release formulations are also contemplated, as are transdermal formulations.

Contemplated for use herein are oral solid dosage forms, which are described generally in Remington's Pharmaceutical Sciences, 18th Ed. 1990 (Mack Publishing Co. Easton PA 18042) at Chapter 89, which is herein incorporated by reference. Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets or pellets. Also, liposomal or proteinoid encapsulation may be used to formulate the present compositions (as, for example, proteinoid microspheres reported in U.S. Patent No. 4,925,673). Liposomal encapsulation may be used and the liposomes may be derivatized with various polymers (E.g., U.S. Patent No. 5,013,556). A description of possible solid dosage forms for the therapeutic is given by Marshall, K. In: *Modern Pharmaceutics* Edited by G.S. Banker and C.T. Rhodes Chapter 10, 1979, herein incorporated by reference. In general, the formulation will include the protein (or analog or derivative), and inert ingredients which allow for protection against the stomach environment, and release of the biologically active material in the intestine.

Also specifically contemplated are oral dosage forms of the above derivatized proteins. Protein may be chemically modified so that oral delivery of the derivative is efficacious. Generally, the chemical modification contemplated is the attachment of at least one moiety to the protein (or peptide) molecule itself, where said moiety permits (a) inhibition of proteolysis; and (b) uptake into the blood stream from the stomach or intestine. Also desired is the increase in overall stability of the protein and increase in circulation time in the body. Examples of such moieties include: Polyethylene glycol, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran,

polyvinyl alcohol, polyvinyl pyrrolidone and polyproline. Abuchowski and Davis, Soluble Polymer-Enzyme Adducts. In: "Enzymes as Drugs", Hocenberg and Roberts, eds., Wiley-Interscience, New York, NY, (1981), pp 367-383; Newmark, et al., J. Appl. Biochem. 4: 185-189 (1982). Other polymers that could be used are poly-1,3-dioxolane and poly-1,3,6-tioxocane.

For the protein (or derivative) the location
10 of release may be the stomach, the small intestine (the duodenum, the jejunum, or the ileum), or the large intestine. One skilled in the art has available formulations which will not dissolve in the stomach, yet will release the material in the duodenum or elsewhere
15 in the intestine. Preferably, the release will avoid the deleterious effects of the stomach environment, either by protection of the protein (or derivative) or by release of the biologically active material beyond the stomach environment, such as in the intestine.

20 To ensure full gastric resistance a coating impermeable to at least pH 5.0 is essential. Examples of the more common inert ingredients that are used as enteric coatings are cellulose acetate trimellitate (CAT), hydroxypropylmethylcellulose phthalate (HPMCP),
25 HPMCP 50, HPMCP 55, polyvinyl acetate phthalate (PVAP), Eudragit L30D, Aquateric, cellulose acetate phthalate (CAP), Eudragit L, Eudragit S, and Shellac. These coatings may be used as mixed films.

30 A coating or mixture of coatings can also be used on tablets, which are not intended for protection against the stomach. This can include sugar coatings, or coatings which make the tablet easier to swallow.
35 Capsules may consist of a hard shell (such as gelatin) for delivery of dry therapeutic i.e. powder; for liquid

forms, a soft gelatin shell may be used. The shell material of cachets could be thick starch or other edible paper. For pills, lozenges, molded tablets or tablet triturates, moist massing techniques can be used.

5

The therapeutic can be included in the formulation as fine multiparticulates in the form of granules or pellets of particle size about 1mm. The formulation of the material for capsule administration 10 could also be as a powder, lightly compressed plugs or even as tablets. The therapeutic could be prepared by compression.

Colorants and flavoring agents may all be 15 included. For example, the protein (or derivative) may be formulated (such as by liposome or microsphere encapsulation) and then further contained within an edible product, such as a refrigerated beverage containing colorants and flavoring agents.

20

One may dilute or increase the volume of the therapeutic with an inert material. These diluents could include carbohydrates, especially mannitol, α -lactose, anhydrous lactose, cellulose, sucrose, 25 modified dextrans and starch. Certain inorganic salts may be also be used as fillers including calcium triphosphate, magnesium carbonate and sodium chloride. Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500, Emcompress and Avicell.

30

Disintegrants may be included in the formulation of the therapeutic into a solid dosage form. Materials used as disintegrates include but are not limited to starch including the commercial disintegrant 35 based on starch, Explotab. Sodium starch glycolate, Amberlite, sodium carboxymethylcellulose,

ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite may all be used. Another form of the disintegrants are the insoluble cationic exchange 5 resins. Powdered gums may be used as disintegrants and as binders and these can include powdered gums such as agar, Karaya or tragacanth. Alginic acid and its sodium salt are also useful as disintegrants.

10 Binders may be used to hold the therapeutic agent together to form a hard tablet and include materials from natural products such as acacia, tragacanth, starch and gelatin. Others include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrrolidone (PVP) and 15 hydroxypropylmethyl cellulose (HPMC) could both be used in alcoholic solutions to granulate the therapeutic.

An antifrictional agent may be included in the 20 formulation of the therapeutic to prevent sticking during the formulation process. Lubricants may be used as a layer between the therapeutic and the die wall, and these can include but are not limited to; stearic acid including its magnesium and calcium salts, 25 polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Soluble lubricants may also be used such as sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol of various molecular weights, Carbowax 4000 and 6000.

30 Glidants that might improve the flow properties of the drug during formulation and to aid rearrangement during compression might be added. The glidants may include starch, talc, pyrogenic silica and 35 hydrated silicoaluminate.

To aid dissolution of the therapeutic into the aqueous environment a surfactant might be added as a wetting agent. Surfactants may include anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents might be used and could include benzalkonium chloride or benzethonium chloride. The list of potential nonionic detergents that could be included in the formulation as surfactants are lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These surfactants could be present in the formulation of the protein or derivative either alone or as a mixture in different ratios.

Additives which potentially enhance uptake of the protein (or derivative) are for instance the fatty acids oleic acid, linoleic acid and linolenic acid.

Controlled release formulation may be desirable. The drug could be incorporated into an inert matrix which permits release by either diffusion or leaching mechanisms i.e. gums. Slowly degenerating matrices may also be incorporated into the formulation. Another form of a controlled release of this therapeutic is by a method based on the Oros therapeutic system (Alza Corp.), i.e. the drug is enclosed in a semipermeable membrane which allows water to enter and push drug out through a single small opening due to osmotic effects. Some entric coatings also have a delayed release effect.

Other coatings may be used for the formulation. These include a variety of sugars which

could be applied in a coating pan. The therapeutic agent could also be given in a film coated tablet and the materials used in this instance are divided into 2 groups. The first are the nonenteric materials and 5 include methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, methylhydroxy-ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, sodium carboxy-methyl cellulose, providone and the polyethylene glycols. The second group consists of the enteric 10 materials that are commonly esters of phthalic acid.

A mix of materials might be used to provide the optimum film coating. Film coating may be carried out in a pan coater or in a fluidized bed or by 15 compression coating.

Also contemplated herein is pulmonary delivery of the present protein, or derivative thereof. The protein (derivative) is delivered to the lungs of a mammal while inhaling and traverses across the lung epithelial lining to the blood stream. (Other reports of this include Adjei et al., Pharmaceutical Research 7: 565-569 (1990); Adjei et al., International Journal of Pharmaceutics 63: 135-144 (1990) (leuprolide acetate); Braquet et al., Journal of Cardiovascular Pharmacology 13(suppl. 5): s.143-146 (1989) (endothelin-1); Hubbard et al., Annals of Internal Medicine 110: 206-212 (1989) (α_1 -antitrypsin); Smith et al., J. Clin. Invest. 84: 1145-1146 (1989) (α -1-proteinase); Oswein et al., "Aerosolization of Proteins", Proceedings of Symposium on Respiratory Drug Delivery II, Keystone, Colorado, March, 1990 (recombinant human growth hormone); Debs et al., The Journal of Immunology 140: 3482-3488 (1988) (interferon- γ 30 and tumor necrosis factor alpha) and Platz et al., U.S. 35

Patent No. 5,284,656 (granulocyte colony stimulating factor)

Contemplated for use in the practice of this
5 invention are a wide range of mechanical devices
designed for pulmonary delivery of therapeutic products,
including but not limited to nebulizers, metered dose
inhalers, and powder inhalers, all of which are familiar
to those skilled in the art.

10

Some specific examples of commercially
available devices suitable for the practice of this
invention are the Ultravent nebulizer, manufactured by
Mallinckrodt, Inc., St. Louis, Missouri; the Acorn II
15 nebulizer, manufactured by Marquest Medical Products,
Englewood, Colorado; the Ventolin metered dose inhaler,
manufactured by Glaxo Inc., Research Triangle Park,
North Carolina; and the Spinhaler powder inhaler,
manufactured by Fisons Corp., Bedford, Massachusetts.

20

All such devices require the use of
formulations suitable for the dispensing of protein (or
analog or derivative). Typically, each formulation is
specific to the type of device employed and may involve
25 the use of an appropriate propellant material, in
addition to diluents, adjuvants and/or carriers useful
in therapy.

The protein (or derivative) should most
30 advantageously be prepared in particulate form with an
average particle size of less than 10 μm (or microns),
most preferably 0.5 to 5 μm , for most effective
delivery to the distal lung.

35 Carriers include carbohydrates such as
trehalose, mannitol, xylitol, sucrose, lactose, and

sorbitol. Other ingredients for use in formulations may include DPPC, DOPE, DSPC and DOPC. Natural or synthetic surfactants may be used. Polyethylene glycol may be used (even apart from its use in derivatizing the protein or analog). Dextrans, such as cyclodextran, may be used. Bile salts and other related enhancers may be used. Cellulose and cellulose derivatives may be used. Amino acids may be used, such as use in a buffer formulation.

10

Also, the use of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated.

15

Formulations suitable for use with a nebulizer, either jet or ultrasonic, will typically comprise protein (or derivative) dissolved in water at a concentration of about 0.1 to 25 mg of biologically active protein per mL of solution. The formulation may also include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure). The nebulizer formulation may also contain a surfactant, to reduce or prevent surface induced aggregation of the protein caused by atomization of the solution in forming the aerosol.

30

Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing the protein (or derivative) suspended in a propellant with the aid of a surfactant. The propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and

1,1,1,2-tetrafluoroethane, or combinations thereof.

Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant.

5

Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing protein (or derivative) and may also include a bulking agent, such as lactose, sorbitol, sucrose, 10 mannitol, trehalose, or xylitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation.

Nasal delivery of the protein (or analog or 15 derivative) is also contemplated. Nasal delivery allows the passage of the protein to the blood stream directly after administering the therapeutic product to the nose, without the necessity for deposition of the product in the lung. Formulations for nasal delivery include those 20 with dextran or cyclodextran. Delivery via transport across other mucus membranes is also contemplated.

One skilled in the art will be able to ascertain effective dosages by administration and 25 observing the desired therapeutic effect. Preferably, the formulation of the molecule will be such that between about .10 µg/kg/day and 10 mg/kg/day will yield the desired therapeutic effect. The effective dosages may be determined using diagnostic tools over time. For 30 example, a diagnostic for measuring the amount of OB protein in the blood (or plasma or serum) may first be used to determine endogenous levels of OB protein. Such diagnostic tool may be in the form of an antibody assay, such as an antibody sandwich assay. The amount of 35 endogenous OB protein is quantified initially, and a baseline is determined. The therapeutic dosages are

determined as the quantification of endogenous and exogenous OB protein (that is, protein, analog or derivative found within the body, either self-produced or administered) is continued over the course of therapy. The dosages may therefore vary over the course of therapy, with a relatively high dosage being used initially, until therapeutic benefit is seen, and lower dosages used to maintain the therapeutic benefits.

Ideally, in situations where solely an increase in lean body mass is desired, the dosage will be insufficient to result in weight loss. Thus, during an initial course of therapy of an obese person, dosages may be administered whereby weight loss and concomitant fat tissue decrease/lean mass increase is achieved. Once sufficient weight loss is achieved, a dosage sufficient to prevent re-gaining weight, yet sufficient to maintain desired lean mass increase (or, prevention of lean mass depletion) may be administered. These dosages can be determined empirically, as the effects of OB protein are reversible. E.g., Campfield et al., Science 269: 546-549 (1995) at 547. Thus, if a dosage resulting in weight loss is observed when weight loss is not desired, one would administer a lower dose in order to achieve the desired increase in lean tissue mass, yet maintain the desired weight.

For increasing an individual's sensitivity to insulin, similar dosage considerations may be taken into account. Lean mass increase without weight loss may be achieved sufficient to decrease the amount of insulin (or, potentially, amylin or other potential diabetes treating drugs) an individual would be administered for the treatment of diabetes.

For increasing overall strength, there may be similar dosage considerations. Lean mass increase with concomitant increase in overall strength may be achieved with doses insufficient to result in weight loss. Other 5 benefits, such as an increase in red blood cells (and oxygenation in the blood) and a decrease in bone resorption or osteoporosis may also be achieved in the absence of weight loss.

The present methods may be used in conjunction 10 with other medicaments, such as those useful for the treatment of diabetes (e.g., insulin, and possibly amylin), cholesterol and blood pressure lowering medicaments (such as those which reduce blood lipid levels or other cardiovascular medicaments), and 15 activity increasing medicaments (e.g., amphetamines). Appetite suppressants may also be used. Such administration may be simultaneous or may be in seriatim.

In addition, the present methods may be used 20 in conjunction with surgical procedures, such as cosmetic surgeries designed to alter the overall appearance of a body (e.g., liposuction or laser surgeries designed to reduce body mass, or implant 25 surgeries designed to increase the appearance of body mass). The health benefits of cardiac surgeries, such as bypass surgeries or other surgeries designed to relieve a deleterious condition caused by blockage of blood vessels by fatty deposits, such as arterial 30 plaque, may be increased with concomitant use of the present compositions and methods. Methods to eliminate gall stones, such as ultrasonic or laser methods, may also be used either prior to, during or after a course 35 of the present therapeutic methods. Furthermore, the present methods may be used as an adjunct to surgeries or therapies for broken bones, damaged muscle, or other

therapies which would be improved by an increase in lean tissue mass.

Therefore, the present invention provides a
5 method for increasing lean tissue mass, comprised of
administering an effective amount of an OB protein,
analog or derivative thereof selected from among:

(a) the amino acid sequence 1-146 as set
forth in SEQ. ID. NO. 2 (below) or SEQ ID. NO. 4
10 (below),

(b) the amino acid sequence set 1-146 as
forth in SEQ. ID. NO. 4 (below) having a lysine residue
at position 35 and an isoleucine residue at position 74;

(c) the amino acid sequence of subpart (b)
15 having a different amino acid substituted in one or more
of the following positions (using the numbering
according to SEQ. ID. NO. 4, and retaining the same
numbering even in the absence of a glutamyl residue at
position 28): 4, 8, 32, 33, 35, 48, 50, 53, 60, 64, 66,
20 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106,
107, 108, 111, 112, 118, 136, 138, 142, and 145;

(d) the amino acid sequence of subparts (a),
(b) or (c) optionally lacking a glutamyl residue at
position 28;

25 (e) the amino acid sequence of subparts (a),
(b), (c), or (d) having a methionyl residue at the N
terminus.

(f) a truncated OB protein analog selected
from among: (using the numbering of SEQ. ID. NO. 4
30 having a lysine residue at position 35 and an isoleucine
residue at position 74):

- (i) amino acids 98-146
- (ii) amino acids 1-32
- (iii) amino acids 40-116
- 35 (iv) amino acids 1-99 and 112-146

(v) amino acids 1-99 and 112-146 having one or more of amino acids 100-111 sequentially placed between amino acids 99 and 112; and,

(vi) the truncated OB analog of subpart

5 (i) having one or more of amino acids 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, and 145 substituted with another amino acid;

(vii) the truncated analog of subpart

10 (ii) having one or more of amino acids 4, 8 and 32 substituted with another amino acid;

(viii) the truncated analog of subpart

15 (ix) having one or more of amino acids 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111 and 112 replaced with another amino acid;

(vix) the truncated analog of subpart

20 (iv) having one or more of amino acids 4, 8, 32, 33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 112, 118, 136, 138, 142, and 145 replaced with another amino acid;

(x) the truncated analog of subpart (v)

25 having one or more of amino acids 4, 8, 32, 33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, and 145 replaced with another amino acid;

(xi) the truncated analog of any of subparts (i)-(x) having an N-terminal methionyl residue; and

30 (g) the OB protein or analog derivative of any of subparts (a) through (f) comprised of a chemical moiety connected to the protein moiety;

(h) a derivative of subpart (g) wherein said chemical moiety is a water soluble polymer moiety;

35 (i) a derivative of subpart (h) wherein said water soluble polymer moiety is polyethylene glycol;

(j) A derivative of subpart (h) wherein said water soluble polymer moiety is a polyamino acid moiety;

5 (k) a derivative of subpart (h) wherein said water soluble polymer moiety is attached at solely the N-terminus of said protein moiety

(l) an OB protein, analog or derivative of any of subparts (a) through (k) in a pharmaceutically acceptable carrier.

10 The following examples are offered to more fully illustrate the invention, but are not to be construed as limiting the scope thereof. Example 1 demonstrates that OB protein is effective for increasing lean mass in non-obese animals. Example 2 demonstrates 15 that OB protein is effective for increasing lean mass in obese primates. Example 3 through 5 are prophetic examples of human use. Materials and Methods follow.

EXAMPLE 1

20 These data demonstrate that the OB protein, or analogs or derivatives thereof, is effective for increasing lean mass.

25 Recombinant methionyl murine OB protein (as described below) was continuously administered via osmotic pump infusion for a period of four weeks. Table 1 data show the average body composition (for CD1 mice) at the dosages indicated:

TABLE 1

Dose (mg/kg/day)	Water (g)	Fat(g)	Lean Mass(g)
PBS	22.13 +/- .33	8.39 +/- .67	3.2 +/- .28
0.03	22.09 +/- .55	9.44 +/- .61	2.32 +/- .54
0.1	21.02 +/- .44	6.64 +/- -1	3.85 +/- .57
0.3	22.02 +/- .31	5.22 +/- .91	4.72 +/- .48
1.0	21.34 +/- .38	1.51 +/- .48	6.94 +/- .25

5 In non-obese CD1 mice, recombinant methionyl murine OB protein continuously administered at doses of either 0.3 or 1 mg/kg/day was shown to effect an increase in lean mass relative to the control animals, who were administered PBS.

10 EXAMPLE 2

This Example demonstrates that recombinant methionyl human OB protein causes lean tissue mass increase in primates.

15 Obese cynomolgus monkeys having greater than 20% body fat were administered recombinant methionyl human OB protein subcutaneously, at a daily dose of 1 mg protein/kg body weight/day (see Materials and Methods, 20 below). Control animals were administered phosphate buffered saline. Body composition was performed using Dual Energy X-Ray Absorptiometry ("DEXA") analysis. Measurements of body composition were taken at 7 day intervals.

25 Tables 2A and 2B show the results of body composition analysis in terms of mass of fat or lean tissue. Data are presented in grams. Results for the 2

control animals are in Table 2A. The data for 4 test animals are presented in Table 2B. (Data for bone mass are also presented). As can be seen, at day 28, the test animals lost approximately 264 grams of fat, and gained approximately 138 grams of lean mass. At day 28, the controls lost 36 grams of fat tissue and gained approximately 25 grams of lean mass. This demonstrates that OB protein causes an increase in lean tissue mass.

10

TABLE 2A

CONTROL (n=2)	BASELINE	DAY 7	DAY 14	DAY 21	DAY 28
LEAN MASS ± STD DEV	5393 ±894	5411 ±863	5467 ±934	5410 ±983	5418 ±802
FAT MASS ± STD DEV	2884 ±1962	2838 ±1936	2835 ±2113	2852 ±2271	2848 ±2122
BONE MASS ± STD DEV	325 ±12	324 ±4	324 ±11	325 ±16	321 ±7

TABLE 2B

OB PROTEIN (n=4)	BASELINE	DAY 7	DAY 14	DAY 21	DAY 28
LEAN MASS ± STD DEV	4877 ±960	4782 ±927	4899 ±1037	4957 ±1053	5015 * ±1192
FAT MASS ± STD DEV	2577 ±1927	2536 ±1982	2432 ±1874	2380 ±1924	2313 * ±1903
BONE MASS ± STD DEV	296 ±96	296 ±99	294 ±97	292 ±96	291 ±96

15

* indicates p-value less than 0.05 for repeated measures ANOVA

20

EXAMPLE 3

A non-obese human patient desires an increase in lean tissue mass for therapeutic purposes, such as
5 recovery from illness which depleted lean tissue mass. The patient is administered an effective amount of OB protein, analog or derivative thereof to result in the desired increase in lean tissue mass. Increase in lean tissue mass is monitored using DEXA scanning. Levels of
10 circulating OB protein or analog or derivative may be monitored using a diagnostic kit, such as an antibody assay against the OB protein (or other antigenic source if applicable).

15 EXAMPLE 4

A human subject desires an increase in lean tissue mass for cosmetic or athletic purposes, such as an increase in lean tissue in order to improve outward appearance. The patient is administered an effective amount of OB protein, analog or derivative thereof to result in the desired increase in lean tissue mass. Increase in lean tissue mass is monitored using DEXA scanning. Oxygen levels in the blood increase. Levels
20 of circulating OB protein or analog or derivative may be monitored using a diagnostic kit, such as an antibody assay against the OB protein (or other antigenic source if applicable).

25 EXAMPLE 5

A diabetic human patient desires to use decreased dosages of insulin for treatment of diabetes. The patient is administered an effective amount of OB protein, analog or derivative thereof to result in an
35 increase in lean tissue mass. The patient's sensitivity

to insulin increases, and the dosage of insulin necessary to alleviate symptoms of diabetes is decreased, either in terms of a decrease in the units of insulin needed, or in terms of a decrease in the number 5 of injections of insulin needed per day. Levels of circulating OB protein or analog or derivative may be monitored using a diagnostic kit, such as an antibody assay against the OB protein (or other antigenic source if applicable).

10

EXAMPLE 6

A non-obese elderly human patient desires an increase in overall strength. The patient is 15 administered an effective amount of OB protein, analog or derivative thereof to result in an increase in lean tissue mass, and increase in overall strength. Bone resorption is also decreased, and an osteoporosis condition is improved. Levels of circulating OB protein 20 or analog or derivative may be monitored using a diagnostic kit, such as an antibody assay against the OB protein (or other antigenic source if applicable).

MATERIALS AND METHODS

25

Animals:

Rodents. Wild type CD1 mice were used for Example 1 (Table 1 data). Animals were maintained under 30 humane conditions.

Primates: A total of six cynomolgus monkeys were used. All monkeys were at least 20% fat at the outset of the study. Animals were randomized for weight, and 35 four animals were tested with OB protein, two animals were controls.

Administration of Protein or Vehicle.

For Rodents. For Example 1, (Table 1 data) recombinant murine protein (as described below) or vehicle (phosphate buffered saline, "PBS", pH 7.4) was administered by osmotic pump infusion. Alzet osmotic minipumps (Alza, Palo Alto, CA, model no. 2002) were surgically placed in each mouse in a subcutaneous pocket in the subscapular area, and replaced after two weeks.

5 The pumps were calibrated to administer 0.5 μ l protein in solution per hour for the dosages indicated in Table 1.

For Primates. For Example 2, recombinant methionyl human OB protein (of SEQ.ID. NO.4 having a lysine at position 35 and an isoleucine at position 74), dosed at 1 mg/ml PBS, was administered subcutaneously at a dose of 1 mg protein/kg body weight/day. Control animals were administered PBS in the same fashion.

15

20 Rodent Carcass Analysis. Carcass analysis was conducted as in A.I. Leshner, V.A. Litwin, and R.L. Squibb, Brain Res. 9: 281 (1972). Water composition was determined by subtraction of carcass weight before and 25 after a 4 day dehydration period. Fat was extracted from a pre-weighed portion of the ground, dried carcass with ethyl ether and ethyl alcohol, so that percent fat could be calculated from the amount of material remaining after the extraction procedure. Lean mass was defined as the proportion of ground carcass that remained after dehydration and ether extraction.

30 Primate Dual Energy X-Ray Absortimetry Scanning: "DEXA" scanning was performed at the time points indicated in Table 2 A and B, in Example 2.

Protein: Sequence ID Nos. 1 and 2 set forth murine recombinant OB DNA and protein, and Sequence ID Nos. 3 and 4 set forth an analog recombinant human OB DNA and protein. Murine recombinant protein as in SEQ. ID NO. 2 was used in EXAMPLE 1. Recombinant human OB protein as in SEQ.ID. NO. 4 having a lysine residue at position 35 and an isoleucine residue at position 74 was used in EXAMPLE 2. As indicated above, the below murine and human analog recombinant proteins are illustrative of the OB protein which may be used in the present methods of treatment and manufacture of a medicament. Other OB proteins or analogs or derivatives thereof may be used.

Herein, the first amino acid of the amino acid sequence for recombinant protein is referred to as +1, and is valine, and the amino acid at position -1 is methionine. The C-terminal amino acid is number 146 (cysteine).

Recombinant murine met OB (double stranded) DNA and amino acid sequence (Seq. ID. Nos. 1 and 2):

9	TCTAGATTTGAGTTTAACTTTAGAAGGAGGAATAACATATGGTACCGATCCAGAAAGT ----- AGATCTAAACTCAAAATTGAAAATCTTCCTTATTGTATACCATGGCTAGGTCTTCA M V P I Q K V -	68
25	TCAGGACGACACCAAAACCTTAATTAAAACGATCGTTACGGCTATCAACGACATCAGTCA ----- AGTCCTGCTGTGGTTGGAAATTAAATTGCTAGCAATGCCATAGTTGCTGTAGTCAGT Q D D T K T L I K T I V T R I N D I S H -	128
30	CACCCAGTCGGTCTCCGCTAACACGCGTGTACCGGTCTGGACTTCATCCCCGGTCTGCA ----- GTGGGTCAGCCAGAGGCAGATTGTCGCACAATGCCAGACCTGAAGTAGGGCCCAGACGT T Q S V S A K Q R V T G L D F I P G L H -	188
35	CCCCGATCTAACGCTTGTCCAAAATGGACCAGACCCCTGGCTGTATACCAACGAGGTGTTAAC ----- GGGCTAGGGATTGCAACAGGTTTACCTGGCTGGGACATATGGTCGTCCACAATTG P I L S L S K M D Q T L A V Y Q Q V L T -	248
40	CTCCCTGCCGTCCCAGAACGTTCTTCAGATCGCTAACGACCTCGAGAACCTCGCGACCT ----- GAGGGACGGCAGGGTCTTGCAGAAGTCTAGCGATTGCTGGAGCTCTGGAAAGCGCTGGA S L P S Q N V L Q I A N D L E N L R D L -	308
45		

309 GCTGCACCTGCTGGCATTCTCAAATCCTGCTCCCTGCCGAGACCTCAGGTCTTCAGAA 368
 CGACGTGGACCGTAAGAGGTTAGGACGAGGGACGGCTCTGGAGTCCAGAAGTCTT
 5 L H L L A F S K S C S L P Q T S G L Q K -
 ACCGGAATCCTGGACGGGGCTGGAAAGCATCCCTGTACAGCACCGAAGTTGGCTCT 428
 369 TGGCCTTAGGGACCTGCCCAAGGACCTTCGTAGGGACATGTCGTGGCTCAACAACGAGA
 10 P E S L D G V L E A S L Y S T E V V A L -
 GTCCCGTCTGCAGGGTCCCTCAGGACATCCTTCAGCAGCTGGACGTTCTCCGGAATG 488
 429 CAGGGCAGACGTCCAAGGGAAGTCCTGTAGGAAGTGTGACCTGCAAAGAGGCCCTAC
 15 S R L Q G S L Q D I L Q Q L D V S P E C -
 TTAATGGATCC
 489 AATTACCTAGG
 20

Recombinant human met OB analog (Double Stranded) DNA and amino acid sequence (SEQ. ID. Nos. 3 and 4)

25 CATATGGTACCGATCCAGAAAGTTCAGGACGACACCAAAACCTTAATTAAAACGATCGTT 60
 1 GTATACCATGGCTAGGTCTTCAGTCCTGCTGTGGTTTGGAATTAAATTGCTAGCAA
 M V P I Q K V Q D D T K T L I K T I V -
 30 ACGCGTATCAACGACATCAGTCACACCCAGTCGGTGAGCTCTAAACAGCGTGTACAGGC 120
 61 TGCGCATAGTTGCTGTAGTCAGTGTGGTCAGCCACTCGAGATTGTCGCACAATGTCCG
 T R I N D I S H T Q S V S S K Q R V T G -
 35 CTGGACTTCATCCGGGTCTGCACCCGATCCTGACCTTGTCCAAATGGACCAGACCTG 180
 121 GACCTGAAGTAGGGCCCAGACGTGGCTAGGACTGGAACAGGTTACCTGGTCTGGAC
 40 L D F I P G L H P I L T L S K M D Q T L -
 45 GCTGTATACCAAGCAGATCTAACCTCCATGCCGTCCGTAACTTCTCAGATCTCTAAC 240
 181 CGACATATGGTCGTCTAGAATTGGAGGTACGGCAGGGCATTGCAAGAAGTCTAGAGATTG
 A V Y Q Q I L T S M P S R N V L Q I S N -
 50 GACCTCGAGAACCTTCGGCACCTGCTGCCACGTGCTGGCATTCTCAAATCCTGCCACCTG 300
 241 CTGGAGCTCTGGAAAGCGCTGGACGACGTGCACGACCGTAAGAGGTTAGGACGGTGGAC
 55 D L E N L R D L L H V L A F S K S C H L -

5 301 CCATGGGCTTCAGGTCTTGAGACTCTGGACTCTCTGGCGGGGCTGGAAAGCATCCGGT
5 GGTACCCGAAGTCCAGAACCTTGAGACCTGAGAGACCCGCCAGGACCTTCGTAGGCCA
5 P W A S G L E T L D S L G G V L E A S G -

10 361 TACAGCACCGAAGTTGTGCTCTGTCCCGTCTGCAGGGTCCCTTCAGGACATGCTTTGG
10 ATGTCTGGCTTCAACAACGAGACAGGGCAGACGTCCCAAGGGAAAGTCCTGTACGAAACC
15 Y S T E V V A L S R L Q G S L Q D M L W -
15 421 CAGCTGGACCTGTCTCCGGTTGTTAATGGATCC
15 GTCGACCTGGACAGAGGCCAACATTACCTAGG
20 Q L D L S P G C *

20

METHODS FOR PRODUCTION

25 The below methods for production have been used
to produce biologically active recombinant methionyl murine
or human analog OB protein. Similar methods may be used to
prepare biologically active recombinant methionyl human OB
protein.

30 Expression Vector and Host Strain

35 The plasmid expression vector used is
pCFM1656, ATCC Accession No. 69576. The above DNA was
ligated into the expression vector pCFM1656 linearized
with XbaI and BamHI and transformed into the *E. coli*
host strain, FM5. *E. coli* FM5 cells were derived at
Amgen Inc., Thousand Oaks, CA from *E. coli* K-12 strain
(Bachmann, et al., Bacteriol. Rev. 40: 116-167 (1976))
40 and contain the integrated lambda phage repressor gene,
cI₈₅₇ (Sussman et al., C.R. Acad. Sci. 254: 1517-1579
(1962)). Vector production, cell transformation, and
colony selection were performed by standard methods.

E.g., Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. Host cells were grown in LB media.

5

Fermentation Process A three-phase fermentation protocol known as a fed-batch process was used. Media compositions are set forth below.

Batch: A nitrogen and phosphate source were
10 sterilized (by raising to 122 °C for 35 minutes, 18-20 psi) in the fermentation vessel (Biolafitte, 12 liter capacity). Upon cooling, carbon, magnesium, vitamin, and trace metal sources were added aseptically. An overnight culture of the above recombinant murine
15 protein-producing bacteria (16 hours or more) of 500 mL (grown in LB broth) was added to the fermentor.

Feed I: Upon reaching between 4.0-6.0 OD₆₀₀, cultures were fed with Feed I. The glucose was fed at a
20 limiting rate in order to control the growth rate (μ). An automated system (called the Distributive Control System) was instructed to control the growth rate to 0.15 generations per hour.

25 Feed II: When the OD₆₀₀ had reached 30, culture temperature were slowly increased to 42°C and the feed changed to Feed II, below. The fermentation was allowed to continue for 10 hours with sampling every 2 hours. After 10 hours, the contents of the fermentor
30 was chilled to below 20°C and harvested by centrifugation.

Media Composition:

Batch: 10 g/L Yeast extract
 5.25 g/L $(\text{NH}_4)_2\text{SO}_4$
 3.5 g/L K_2HPO_4
5 4.0 g/L KH_2PO_4
 5.0 g/L Glucose
 1.0 g/L $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$
 2.0 mL/L Vitamin Solution
 2.0 mL/L Trace Metal Solution
10 1.0 mL/L P2000 Antifoam
Feed I: 50 g/L Bacto-tryptone
 50 g/L Yeast extract
 450 g/L Glucose
 8.75 g/L $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$
15 10 mL/L Vitamin Solution
 10 mL/L Trace Metal Solution
Feed II: 200 g/L Bacto-tryptone
 100 g/L Yeast extract
 110 g/L Glucose

20

Vitamin Solution (Batch and Feed I):

0.5 g Biotin, 0.4 g Folic acid, and 4.2 g riboflavin,
was dissolved in 450 mls H_2O and 3 mls 10 N NaOH, and
brought to 500 mLs in H_2O . 14 g pyridoxine-HCl and 61 g
niacin was dissolved 150 ml H_2O and 50 ml 10 N NaOH, and
brought to 250 ml in H_2O . 54 g pantothenic acid was
dissolved in 200 mL H_2O , and brought to 250 mL. The
three solutions were combined and brought to 10 liters
total volume.

30

Trace Metal Solution (Batch and Feed I):

Ferric Chloride ($\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$): 27 g/LZinc Chloride ($\text{ZnCl}_2 \cdot 4\text{H}_2\text{O}$): 2 g/LCobalt Chloride ($\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$): 2 g/L35 Sodium Molybdate ($\text{NaMoO}_4 \cdot 2\text{H}_2\text{O}$): 2 g/LCalcium Chloride ($\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$): 1 g/L

Cupric Sulfate ($\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$): 1.9 g/L

Boric Acid (H_3BO_3): 0.5 g/L

Manganese Chloride ($\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$): 1.6 g/L

Sodium Citrate dihydrate: 73.5 g/L

5

Purification Process for Murine OB Protein

Purification was accomplished by the following steps (unless otherwise noted, the following steps were performed at 4°C):

10

1. Cell paste. *E. coli* cell paste was suspended in 5 times volume of 7 mM of EDTA, pH 7.0. The cells in the EDTA were further broken by two passes through a microfluidizer. The broken cells were centrifuged at 15 4.2 K rpm for 1 hour in a Beckman J6-B centrifuge with a JS-4.2 rotor.

2. Inclusion body wash #1. The supernatant from above was removed, and the pellet was resuspended with 20 5 times volume of 7 mM EDTA, pH 7.0, and homogenized. This mixture was centrifuged as in step 1.

3. Inclusion body wash #2. The supernatant from above was removed, and the pellet was resuspended in ten 25 times volume of 20 mM tris, pH 8.5, 10 mM DTT, and 1% deoxycholate, and homogenized. This mixture was centrifuged as in step 1.

4. Inclusion body wash #3. The supernatant from 30 above was removed and the pellet was resuspended in ten times volume of distilled water, and homogenized. This mixture was centrifuged as in step 1.

35 5. Refolding. The pellet was refolded with 15 volumes of 10 mM HEPES, pH 8.5, 1% sodium sarcosine

(N-lauroyl sarcosine), at room temperature. After 60 minutes, the solution was made to be 60 μ M copper sulfate, and then stirred overnight.

5 6. Removal of sarcosine. The refolding mixture was diluted with 5 volumes of 10 mM tris buffer, pH 7.5, and centrifuged as in step 1. The supernatant was collected, and mixed with agitation for one hour with Dowex® 1-X4 resin (Dow Chemical Co., Midland MI), 20-50 10 mesh, chloride form, at 0.066% total volume of diluted refolding mix. See WO 89/10932 at page 26 for more information on Dowex®. This mixture was poured into a column and the eluant collected. Removal of sarcosine was ascertained by reverse phase HPLC.

15 7. Acid precipitation. The eluant from the previous step was collected, and pH adjusted to pH 5.5, and incubated for 30 minutes at room temperature. This mixture was centrifuged as in step 1.

20 8. Cation exchange chromatography. The pH of the supernatant from the previous step was adjusted to pH 4.2, and loaded on CM Sepharose Fast Flow (at 7% volume). 20 column volumes of salt gradient were done 25 at 20 mM NaOAC, pH 4.2, 0 M to 1.0 M NaCl.

30 9. Hydrophobic interaction chromatography. The CM Sepharose pool of peak fractions (ascertained from ultraviolet absorbance) from the above step was made to be 0.2 M ammonium sulfate. A 20 column volume reverse salt gradient was done at 5 mM NaOAC, pH 4.2, with .4 M to 0 M ammonium sulfate. This material was concentrated and diafiltered into PBS.

35 Fermentation of recombinant human OB protein analog: Fermentation of the above host cells to produce

recombinant human OB protein analog (SEQ. ID. NO. 4) can be accomplished using the conditions and compositions as described above for recombinant murine material.

5 Purification of the recombinant human OB protein analog: Recombinant human protein analog may be purified using methods similar to those used for purification of recombinant murine protein, as in Example 1, above. For preparation of recombinant human
10 OB protein analog, step 8 should be performed by adjusting the pH of the supernatant from step 7 to pH 5.0, and loading this onto a CM Sepharose fast flow column. The 20 column volume salt gradient should be performed at 20 mM NaOAC, pH 5.5, 0M to 0.5 M NaCl.
15 Step 9 should be performed by diluting the CM Sepharose pool four fold with water, and adjusting the pH to 7.5. This mixture should be made to 0.7 M ammonium sulfate. Twenty column volume reverse salt gradient should be done at 5 mM NaOAC, pH 5.5, 0.2 M to 0M ammonium
20 sulfate. Otherwise, the above steps are identical. For EXAMPLE 2 material, the recombinant human OB protein of SEQ.ID.NO.4 having lysine 35 and isoleucine 74 was formulated in a buffer containing 10 mM histidine, 4.3% arginine, at pH 6.0.

25 While the present invention has been described in terms of preferred embodiments, it is understood that variations and modifications will occur to those skilled in the art. Therefore, it is intended that the appended
30 claims cover all such equivalent variations which come within the scope of the invention as claimed.

CLAIMS

1. A method for increasing lean tissue mass, comprised of administering an effective amount of an OB protein, analog or derivative thereof selected from among:

- (a) the amino acid sequence 1-146 as set forth in SEQ. ID. NO. 2 or SEQ ID. NO. 4;
- 10 (b) the amino acid sequence 1-146 as set forth in SEQ. ID. NO. 4 having a lysine residue at position 35 and an isoleucine residue at position 74;
- (c) the amino acid sequence of subpart (b) having a different amino acid substituted in one or more of the following positions (using the numbering 15 according to SEQ. ID. NO. 4): 4, 8, 32, 33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, and 145;
- 20 (d) the amino acid sequence of subparts (a), (b) or (c) optionally lacking a glutaminyl residue at position 28;
- (e) the amino acid sequence of subparts (a), (b), (c), or (d) having a methionyl residue at the N terminus.
- 25 (f) a truncated OB protein analog selected from among: (using the numbering of SEQ. ID. NO. 4 having a lysine residue at position 35, and an isoleucine residue at position 74):
 - (i) amino acids 98-146
 - 30 (ii) amino acids 1-32
 - (iii) amino acids 40-116
 - (iv) amino acids 1-99 and 112-146
 - (v) amino acids 1-99 and 112-146 having one or more of amino acids 100-111 sequentially placed between amino acids 99 and 112; and,

- (vi) the truncated OB analog of subpart
(f)(i) having one or more of amino acids 100, 102,
105, 106, 107, 108, 111, 112, 118, 136, 138, 142,
and 145 substituted with another amino acid;
- 5 (vii) the truncated analog of subpart
(f)(ii) having one or more of amino acids 4, 8 and
32 substituted with another amino acid;
- (viii) the truncated analog of subpart
10 (f)(iii) having one or more of amino acids 50, 53,
60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100,
102, 105, 106, 107, 108, 111 and 112 replaced with
another amino acid;
- (vix) the truncated analog of subpart
15 (f)(iv) having one or more of amino acids 4, 8, 32,
33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77,
78, 89, 97, 112, 118, 136, 138, 142, and 145
replaced with another amino acid;
- (x) the truncated analog of subpart
20 (f)(v) having one or more of amino acids 4, 8, 32,
33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74,
77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111,
112, 118, 136, 138, 142, and 145 replaced with
another amino acid;
- (xi) the truncated analog of any of
25 subparts (f)(i)-(x) having an N-terminal methionyl
residue; and
- (g) the OB protein or analog derivative of
any of subparts (a) through (f) comprised of a chemical
moiety connected to the protein moiety;
- 30 (h) a derivative of subpart (g) wherein said
chemical moiety is a water soluble polymer moiety;
- (i) a derivative of subpart (h) wherein said
water soluble polymer moiety is polyethylene glycol;
- (j) A derivative of subpart (h) wherein said
35 water soluble polymer moiety is a polyamino acid moiety;

(k) a derivative of subpart (h) wherein said water soluble polymer moiety is attached at solely the N-terminus of said protein moiety;

5 (l) an OB protein, analog or derivative of any of subparts (a) through (k) in a pharmaceutically acceptable carrier.

2. A method of claim 1 wherein said method also provides for an increased sensitivity to insulin.

10

3. A method of claim 1 wherein said method also provides for an increase in overall body strength.

15 4. A method of claim 1 wherein said method also provides for decreased bone resorption.

INTERNATIONAL SEARCH REPORT

Int. Application No.
PCT/US 96/17718

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K38/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 05309 A (PUTZMEISTER MASCHF ;WANNER MARTIN (DE); HERKOMMER THOMAS FRED (DE)) 23 February 1995 see page 88, line 6 - line 16; claims; examples ---	1,2
A	NATURE, vol. 372, no. 6505, 1 December 1994, pages 425-432, XP000602062 YIYING ZHANG ET AL: "POSITIONAL CLONING OF THE MOUSE OBESE GENE AND ITS HUMAN HOMOLOGUE" see page 431, left-hand column, paragraph 2 - right-hand column, last paragraph ---	1 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

1

Date of the actual completion of the international search 25 March 1997	Date of mailing of the international search report 07.04.97
--	--

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl.
Fax (+ 31-70) 340-3016

Authorized officer

Fuhr, C

INTERNATIONAL SEARCH REPORT

In National Application No
PCT/US 96/17718

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 362 999 A (BUNGE AUSTRALIA) 11 April 1990 see page 2, line 8 - line 12 see page 3, line 46 - line 50; claims; examples ---	1
A	EP 0 306 673 A (ENIRICERCHE SPA) 15 March 1989 see page 2, line 14 - line 15; claims; examples ---	1
A	WO 91 11111 A (UNIV IOWA RES FOUND) 8 August 1991 see page 4, paragraph 2 - page 5, paragraph 1; claims; examples -----	1

1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/17718

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 1-4
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: As far as claims 1 to 4 are directed to a method of treatment of or diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

In national Application No

PCT/US 96/17718

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9505309 A	23-02-95	AU 7535394 A AU 7613394 A DE 4428146 A DE 4428734 A WO 9505310 A EP 0711236 A JP 9501373 T	14-03-95 14-03-95 16-02-95 23-02-95 23-02-95 15-05-96 10-02-97
EP 0362999 A	11-04-90	AU 618396 B AU 4020389 A CA 1335712 A JP 2156861 A	19-12-91 01-03-90 30-05-95 15-06-90
EP 0306673 A	15-03-89	DE 3879823 A ES 2053635 T JP 2000446 A JP 7004254 B US 5268277 A	06-05-93 01-08-94 05-01-90 25-01-95 07-12-93
WO 9111111 A	08-08-91	US 5028440 A AU 627111 B AU 7338691 A CA 2050572 A DE 69101595 D DE 69101595 T EP 0465646 A JP 4506606 T US 5087472 A	02-07-91 13-08-92 21-08-91 31-07-91 11-05-94 21-07-94 15-01-92 19-11-92 11-02-92